This study investigated the effects of zinc deficiency and supplementation on oxidative stress markers and the expression of ZnT3, NOGO-A, IL-6, and SESN2 in hippocampal tissue within a cuprizone (CPZ)-induced toxic demyelination model. Methods: Forty-six adult male Wistar rats were divided into five groups: Control (n = 6), Sham (n = 10), CPZ (n = 10), CPZ + zinc-deficient diet (n = 10), and CPZ + zinc supplementation (5 mg/kg/day, i.p., n = 10). Toxic demyelination was induced by continuous cuprizone administration for eight weeks. At the end of the experimental period, hippocampal malondialdehyde (MDA) and glutathione (GSH) levels were measured; additionally, hippocampal ZnT3, NOGO-A, IL-6, and SESN2 mRNA expression levels were analyzed using quantitative real-time PCR. Cuprizone administration led to significant hippocampal oxidative stress, characterized by increased MDA levels and decreased GSH concentrations (p < 0.05); these oxidative changes were further exacerbated in CPZ-treated animals fed a zinc-deficient diet (p < 0.05). Furthermore, CPZ-induced demyelination suppressed ZnT3 expression in hippocampal tissue while significantly increasing NOGO-A, IL-6, and SESN2 mRNA expression (p < 0.05). These molecular alterations were more pronounced in the zinc-deficient CPZ group (p < 0.05). Intraperitoneal zinc supplementation effectively mitigated these changes by suppressing oxidative stress, attenuating the upregulation of NOGO-A, IL-6, and SESN2 transcripts, and restoring ZnT3 expression to levels comparable to controls (p < 0.05). While dietary zinc deficiency exacerbated hippocampal oxidative stress, neuroinflammatory transcripts, and molecular markers associated with neurodegeneration in the cuprizone model, zinc supplementation restored oxidative balance; increased ZnT3 expression; and suppressed the upregulation of NOGO-A, IL-6, and SESN2. These findings suggest that zinc homeostasis significantly modulates cuprizone-induced hippocampal damage and that zinc supplementation may exert protective transcriptional and antioxidant effects during toxic demyelination.
No takes yet. Share an insight, caveat, or question.
Atacak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: